A novel method named Perturbed Flow Matching (PFM), which significantly reduces sampling steps by leveraging a Flow Matching framework and introduces a unique perturbed conditional probability path design that incorporates pocket binding site information and atom type-coordinate coupled information to enhance molecular generation performance.
Drug discovery and development is time-consuming and resource-intensive, motivating computational approaches such as diffusion models for de novo drug design. Many such models follow the structure-based drug design (SBDD) paradigm, generating molecules to fit a target binding pocket. However, existing diffusion-based SBDD methods typically couple pocket and ligand representation learning, model interactions only at the atom level, and prioritize binding affinity over other developability properties. Here, we introduce conDitar-dev, a conditional diffusion-based SBDD framework for generating ligands with strong binding affinities and favorable ADMET properties. It consists of three modules: msPRL, a pretrained multi-scale pocket representation learning module; conDitar, a pocket-conditioned diffusion model guided by msPRL representations; and paOPT, a generation-time method for optimizing ligand developability. On a newly curated benchmark of human disease targets, conDitar outperforms state-of-the-art SBDD baselines, achieving an average binding score of -8.85 kcal/mol. Across five ADMET properties, conDitar-dev improves performance by up to 73% over conDitar. To further validate the abilities of conDitar-dev to generate developable molecules, we have applied it to two validated druggable targets: programmed death-ligand 1 (PD-L1) and colony-stimulating factor 1 receptor (CSF1R) proteins. Top-ranked generatively designed molecules and their analogs have been experimentally synthesized and biologically tested. Two molecules generated directly by conDitar-dev for PD-L1 exhibited SPR-derived $K_D$ values of 3.49 and 3.75 $\mu$M, respectively. Hit expansion based on conDitar-dev-designed molecules identified selective CSF1R inhibitors with IC$_{50}$ values as low as 200 nM, while also uncovering opportunities for drug repositioning.
Ruoxi Gao, Jiangweizhi Peng, Ziqi Chen et al.· 0 citations
A clear pattern is revealed in LLM spatial capabilities: while they still lag behind state-of-the-art approaches, they are promising and can handle multiple spatial constraints simultaneously, enabling scaling to heterogeneous setups.
Thomas MacDougall, Maksim Kuznetsov, Roman Schutski et al.· 0 citations
Small-molecule drug discovery relies on iterative molecular optimization, where chemists repeatedly modify candidate compounds to balance multiple competing properties such as efficacy, toxicity, and solubility. Recent advances in generative AI (GenAI) have shown promise in accelerating this process by automatically proposing new molecular structures or targeted modifications. However, existing GenAI-based molecular design tools remain poorly aligned with experts'real-world workflows. Specifically, they offer limited support for specifying structure-level modification intents on molecules, provide insufficient transparency into model-generated modifications, and lack integrated support for downstream property evaluation with external computational tools. To address these challenges, we introduce MolecularCanvas, an interactive system that enables users to iteratively construct an optimization context by integrating high-level goals, structure-level annotations, property constraints, and reference-based preferences. This context guides the generation of candidate molecules across diverse molecular structures. MolecularCanvas further enhances transparency by providing evidence for AI-generated suggestions and streamlines molecular evaluation by integrating commonly used computational tools for property assessment into a unified interface. Finally, a user study with 12 participants demonstrates the usefulness and effectiveness of MolecularCanvas in helping users optimize candidate molecules.
Haoyu Dong, Rui Sheng, Shuhao Zhang et al.· 0 citations
Current structure-based drug design generative models often struggle to faithfully recapitulate genuine ligand-protein binding interactions. Instead, under the coupling of implicit learning architectures and biased training data, they tend to learn spurious statistical correlations. To address this, we propose EIP-Diff (Explicit Interaction-Prompted Diffusion), an architecture featuring a novel explicit interaction-prompt embedding mechanism that is better suited for real-world target-specific drug design. This architecture replaces biased implicit learning with explicit, residue-level biological guidance, thereby promoting more fine-grained geometric fidelity and more precise interaction-aware conditioning. To fully realize the capabilities of EIP-Diff and provide a reliable basis for performance evaluation, we further constructed CrystalData set, which provides higher-fidelity and less-biased structural supervision than existing data sets. This explicit architecture markedly improves distribution consistency: even when trained on the crossdocked data set, EIP-Diff achieves the highest alignment with authentic pharmacological distributions among evaluated models. Training on CrystalData set further enhances this alignment and improves 3D geometric accuracy, while retaining strong controllability, high chemical space coverage, and near-perfect uniqueness. In addition, target-based validation on KAT6A and YTHDC1 confirmed that EIP-Diff accurately recapitulates native-like binding modes. Furthermore, in a real-world drug design task against IDO1, we successfully designed a novel lead compound with nanomolar potency (IC50 = 0.31 nM). These results demonstrate that the EIP-Diff architecture can explicitly leverage experimentally derived structural data and biologically meaningful interaction information for target-specific molecular generation, thereby enabling its effective application to real-world structure-based drug design.
Huabin Du, Mingyang Wang, M. Luo et al.· Journal of the American Chem...· 0 citations
Protein-ligand co-folding models hold promise in structure-based drug discovery and small molecule interaction prediction, but often fail in predicting correct small molecule binding poses. We present Boltz-Perturb, a framework for addressing this through perturbing model conditioning signals during model inference, and show that such perturbations improve correct ligand binding mode predictions. We first show with true-coordinate injection experiments that the model’s learned energy landscape contains correct binding-mode basins, allowing us to reframe the problem as one of sampling deficiency. We then introduce two inference-time perturbation strategies, Token Bias Perturbation (TBP) and Token Conditioning Perturbation (TCP), which increase exploration of alternative binding poses. Across diverse protein–ligand systems, TCP improves top-20 oracle success rates by 2.6 to 7.8 fold. Boltz-Perturb attains higher oracle success rates compared to the Boltz-2 high diffusion temperature variant while requiring over 75% less compute. To our knowledge, this is the first systematic perturbation analysis of a co-folding architecture for small-molecule binding mode diversity. We demonstrate that inference-time perturbations can unlock latent structural diversity in generative co-folding models and improve protein-ligand predictions without costly retraining.
Hyeyun Jung, BoRam Lee, Alan C. Cheng· bioRxiv· 0 citations
A state-aware functional classifier (SAFC) is developed that integrates molecular dynamics derived receptor ensembles, ensemble docking and protein ligand interaction graphs that provides dynamics-aware functional activity rankings for generated molecules that were partly complementary to docking, drug-likeness and synthetic accessibility scores.
H. Kumar, Zhengxiao Yang, Yankai Yu et al.· bioRxiv· 0 citations